News
EPRX
7.55
-0.79%
-0.06
Eupraxia Pharmaceuticals Reports Stronger Balance Sheet but Wider Q1 2026 Loss in Form 6-K Filing
TipRanks · 1d ago
Eupraxia Pharmaceuticals reports Q1 net loss ($12.7M) vs. ($6.8M) last year
TipRanks · 1d ago
Eupraxia Pharmaceuticals publishes MD&A for three months ended March 31, 2026
PUBT · 1d ago
Eupraxia Pharmaceuticals reports Q1 results
Seeking Alpha · 1d ago
Eupraxia Pharmaceuticals Q1 EPS $(0.23) Misses $(0.22) Estimate
Benzinga · 1d ago
Weekly Report: what happened at EPRX last week (0504-0508)?
Weekly Report · 2d ago
Eupraxia Pharmaceuticals Posts Strong Histologic Gains in Mid-Stage EoE Trial for EP-104GI
TipRanks · 05/06 11:30
Eupraxia reports RESOLVE trial EoEHSS subscore improvements for EP-104GI in EoE
PUBT · 05/06 11:16
Eupraxia reports EP-104GI RESOLVE trial EoEHSS subscore improvements in eosinophilic esophagitis
PUBT · 05/06 11:09
Stocks in play: Eupraxia Pharmaceuticals Inc.
Barchart · 05/06 08:11
Craig-Hallum Sticks to Their Buy Rating for Eupraxia Pharmaceuticals (EPRX)
TipRanks · 05/05 14:05
Eupraxia Pharmaceuticals Highlights Strong EP-104GI EoE Data From RESOLVE Trial at DDW
TipRanks · 05/05 11:33
Eupraxia Reports Early Trial Results For EoE Drug, Doses Show Response In Mid-Stage Study
Benzinga · 05/05 11:15
Eupraxia reports RESOLVE trial EREFS improvements for EP-104GI in eosinophilic esophagitis
PUBT · 05/05 11:04
Buy Rating Backed by Favorable Safety and Promising Efficacy Data for EP-104GI in Eosinophilic Esophagitis
TipRanks · 05/04 19:45
HC Wainwright & Co. Reiterates Buy on Eupraxia Pharmaceuticals, Maintains $11 Price Target
Benzinga · 05/04 16:49
H.C. Wainwright Remains a Buy on Eupraxia Pharmaceuticals (EPRX)
TipRanks · 05/04 15:15
Weekly Report: what happened at EPRX last week (0427-0501)?
Weekly Report · 05/04 09:41
Eupraxia Pharmaceuticals Names New Chief Medical Officer to Steer Late-Stage Pipeline
TipRanks · 05/01 22:50
Eupraxia Pharmaceuticals names Dr. Jeymi Tambiah as Chief Medical Officer
TipRanks · 05/01 21:10
More
Webull provides a variety of real-time EPRX stock news. You can receive the latest news about Eupraxia Pharmac through multiple platforms. This information may help you make smarter investment decisions.
About EPRX
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. The Company is focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. DiffuSphere, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The Company’s EP-104GI is in a Phase Ib/IIa trial, the RESOLVE trial, for the treatment of eosinophilic esophagitis (EoE). EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. The Company also completed a Phase IIb clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. In addition, the Company is developing a pipeline of later and earlier-stage long-acting formulations. Its potential pipeline indications include candidates for other inflammatory joint indications and oncology.